Clotting Parameters After Medical Abortion

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Total Enrollment

45 participants

Study Classification

OBSERVATIONAL

Study Start Date

2021-03-26

Study Completion Date

2021-08-12

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Venous thromboembolism (VTE - blood clots that form in deep veins or in the lungs) has been identified as a leading cause of death in economically developed countries for pregnant and recently-pregnant women.

There is evidence that clotting parameters can take up to 6 weeks to return to normal for women who have had term deliveries, however there is an absence of information on time taken for clotting parameters to normalise following abortion.

As such, existing guidelines are based solely on expert opinion and recommend durations of VTE prevention from as short as 7 days, up to 6 weeks following abortion.

All women are assessed for risk of VTE, but data are needed to inform an evidence-based approach to prevention of VTE in these women.

The findings from this pilot study have the potential to inform clinical guidance and possibly a larger study subsequently.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Comparison of Low and Intermediate Dose Low-molecular-weight Heparin to Prevent Recurrent Venous Thromboembolism in Pregnancy

NCT01828697

Deep Venous Thrombosis Pulmonary Embolism

COMPLETED PHASE4

Prevention of Postpartum Venous Thromboembolism in Women at Intermediate Risk

NCT06845423

Venous Thromboembolism (VTE) Post Partum Women

RECRUITING PHASE4

Dalteparin vs Unfractionated Heparin For The Prevention Of Venous Thromboembolism (VTE) In Hospitalized Acutely Ill Medical Patients

NCT00445328

Venous Thromboembolism

TERMINATED PHASE4

Evaluation of an Antithrombotic Therapeutic Strategy in Pregnant Women

NCT00745212

Placental Vascular Pathologies Venous Thromboembolism Diseases

COMPLETED

Thrombin Generation and Gestational Outcome

NCT02139670

Thrombophilia

COMPLETED

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Sample population: Women who attend the abortion service at the Chalmers Centre to receive abortion assessment and abortion care. There will be 3 groups recruited based upon gestational age of pregnancy - Group 1: Gestation less than 10 weeks (10 participants), Group 2: Gestation 10+0 -13+6 weeks (10 participants), Group 3: Gestation 14+0-20+0 weeks (10 participants).

Information Sheet: All new patients attending the clinic will be given a copy of the participant information sheet, so that they have time to read about the study. The Information sheet will also be available on the 'research' section of the clinic website - all women are routinely directed to this page before attending clinic.

Approach by research staff: Following registration, all patients are taken for an ultrasound scan by a clinical support worker to confirm gestation. Following this, patients move to a waiting area until they can be seen for their assessment. While they are waiting, the clinic coordinator will ask the patient if they are happy to be approached by the researcher to discuss the study further. If they are happy to discuss further, the researcher will then approach and discuss the study in a private room.

Consent: If patients are happy to participate in the study, the researcher will then obtain written informed consent prior to their bloods being taken by clinic staff if bloods required for routine care, if no routine bloods are required, the researcher will obtain the blood sample. Participants will be asked if they are planning to use a hormonal form of contraception following their abortion - if yes, they would be asked to wait until they have had their second blood sample taken to commence or not taken forward into the study.

First blood test: This will be obtained on the day of clinic attendance and ultrasound scan. Blood samples (less than 20 ml) will be obtained and taken to the NHS Lothian laboratory at the Royal Infirmary of Edinburgh and for ClotPro thromboelastography point of care testing.

Second blood test: An appointment will be made to see the patient in Chalmers Centre or at their home to obtain a further blood sample to compare to the initial test. This will take place 10-14 days following mifepristone administration. For the repeat sample we will conduct a COVID-19 risk assessment and only invite them for return visit/home visit if:

1. The participant has confirmed they and close contacts are well and without suspicion of COVID-19.
2. The participant agrees to a home visit.
3. The research staff undertaking the home visit should be well and have had no known contact with a COVID-19 positive individual for the past 14 days.

If they are having an intrauterine contraceptive, implant or injection, the second blood sample can be taken when they come into clinic for this, to minimise the number of visits.

Comparison group: A comparison group, Group 4 (10 participants), who are healthy volunteers, recruited from sexual and reproductive health clinics at Chalmers Centre, will be asked to provide a single blood test for ClotPro and lab tests, and urine pregnancy test hCG to act as a nonpregnant comparison. These participants must not be using hormonal contraception and must not be pregnant. This group will be approached by clinicians working in the SRH clinics and the researcher will be on hand to obtain consent and then draw blood.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Abortion Early Abortion, Complete Abortion, Second Trimester Termination of Pregnancy Complicated by Embolism Venous Thromboses Venous Thromboembolism Venous Thromboembolic Disease Clotting Disorder

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

COHORT

Study Time Perspective

PROSPECTIVE

Serum human chorionic gonadotrophin

Intervention Type DIAGNOSTIC_TEST

Pregnancy Test

Point of care urinary pregnancy test

Intervention Type DIAGNOSTIC_TEST

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

Group 1:

* Pregnant and seeking abortion
* Gestation of pregnancy less than 10 weeks
* Healthy, no medical conditions

Group 2:

* Pregnant and seeking abortion
* Gestation of pregnancy between 10 and 14 weeks
* Healthy, no medical conditions

Group 3:

* Pregnant and seeking abortion
* Gestation of pregnancy between 14 to 20 weeks
* Healthy, no medical conditions

Group 4:

* Non pregnant
* Healthy, no medical conditions
* Able to speak English independently

Exclusion Criteria

All groups:

* Unable to give informed consent
* Previous or current venous thromboembolism
* Current smoker
* Personal or family history of thrombophilia or haemophilia
* Taking medicines known to affect clotting parameters (e.g. Aspirin)

Groups 1-3:

\- Planning to commence hormonal contraception prior to second blood test.

Group 4:

\- Using hormonal contraception at baseline visit

Minimum Eligible Age

16 Years

Eligible Sex

FEMALE

Accepts Healthy Volunteers

Yes